(Q100152343)

English

ERBB2 KD mutants heterodimerize

An instance of the biological reaction in Homo sapiens with Reactome ID (R-HSA-9664567)

In more languages

default for all languages

No label defined

No description defined

edit

Statements

1 reference

8 July 2022

Signaling by ERBB2 KD Mutants

1 reference

8 July 2022

1 reference

8 July 2022

https://identifiers.org/reactome:R-HSA-9664567

1 reference

8 July 2022

ERBB2 KD mutants:ERBIN:HSP90:CDC37 [plasma membrane]

quantity

1

object of statement has role

1 reference

8 July 2022

Ligand-Activated (EGFR,ERBB3,ERBB4) [plasma membrane]

quantity

1

object of statement has role

1 reference

8 July 2022

1

object of statement has role

1 reference

8 July 2022

Erbb2 interacting protein

quantity

1

object of statement has role

1 reference

8 July 2022

Heterodimers of ERBB2 KD mutants [plasma membrane]

quantity

1

object of statement has role

1 reference

8 July 2022

1

object of statement has role

1 reference

8 July 2022

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

1 reference

8 July 2022

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

8 July 2022

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

1 reference

8 July 2022

Anti-tumor effect of neratinib against lung cancer cells harboring oncogene alterations

1 reference

8 July 2022

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

1 reference

8 July 2022

Combined blockade of activating mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer

1 reference

8 July 2022

Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface

1 reference

8 July 2022

Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism

1 reference

8 July 2022

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

1 reference

8 July 2022

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

8 July 2022

Identifiers

1 reference

8 July 2022

(Q100152343)

ERBB2 KD mutants heterodimerize

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)